Nuwellis Inc. (NASDAQ: NUWE) announced an expanded collaboration with a South Carolina healthcare system to install Aquadex SmartFlow devices at one of its children's hospitals. The medical technology company also upgraded existing Aquadex devices at two locations within the healthcare system that already use the technology.

The Aquadex system provides ultrafiltration therapy for adult and pediatric patients weighing 20 kg and above who suffer from fluid overload. The therapy is designed to support patient management and may help reduce rehospitalizations related to heart failure and similar conditions.

"Expanding this important collaboration will bring our Aquadex therapy to more pediatric patients in need," said CEO John Erb. "This further validates Nuwellis' ultrafiltration system as a clinically important and increasingly adopted solution for managing fluid overload."

The Minneapolis-based company completed a pre-submission meeting with the U.S. Food and Drug Administration to propose expanding the Aquadex SmartFlow System's label to support pediatric patients weighing 5 kg and above. Nuwellis expects to submit the proposal to the FDA by the end of 2026.

Nuwellis develops solutions for patients with cardiorenal conditions, focusing on monitoring, therapy, and clinical decision-making across acute and chronic care settings. The company's portfolio includes commercially available and development-stage technologies addressing cardiorenal conditions.